Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
Tuesday, Cantor Fitzgerald initiated coverage on Inflarx NV (NASDAQ:IFRX) with an Overweight rating and established a price target of $10.00, adding to the strong analyst consensus with targets ranging from $5.24 to $13.63. According to InvestingPro analysis, the stock appears undervalued at current levels. The firm highlighted the potential impact of the upcoming Phase 3 interim analysis for the company’s primary drug candidate, vilobelimab, which is being developed to treat pyoderma gangrenosum (PG), a rare skin condition.
The analysts at Cantor Fitzgerald pointed out that the interim analysis, scheduled for May 2025, could serve as a significant catalyst for Inflarx stock. They believe that the market has not fully appreciated the potential of this event. InvestingPro data shows the company maintains a healthy balance sheet with more cash than debt and a current ratio of 5.06, though it’s currently burning through cash rapidly. According to their report, the risk/reward profile leading into the interim analysis of the blinded study could be highly favorable, with the possibility of gaining valuable insights from the data.
Inflarx’s second asset, INF904, was also mentioned as a promising drug candidate. The analysts suggested that INF904 could be a superior C5aR inhibitor compared to the FDA-approved Tavneos, which is currently available on the market.
The research firm’s positive outlook on Inflarx is based on a statistical analysis included in their report. This analysis supports their conclusion that the upcoming interim analysis could positively skew the risk/reward balance for Inflarx stock.
Inflarx NV is focused on the development of drugs to treat inflammatory diseases through the inhibition of the complement system, which is a part of the immune system. The company’s lead candidate, vilobelimab, targets the C5a component, which plays a significant role in inflammation. With a market capitalization of $82.47 million and significant stock price volatility over the past year, investors seeking deeper insights can access additional financial metrics and analysis through InvestingPro, which offers 8 more exclusive tips about IFRX’s financial health and market position.
In other recent news, Inflarx has announced a public offering of its ordinary shares and pre-funded warrants, with the intention of using the proceeds to advance its clinical pipeline, including the development of vilobelimab and INF904. This offering is subject to market conditions and does not guarantee completion or specific terms. Guggenheim Securities is managing the offering, which follows the U.S. Securities and Exchange Commission’s approval of a shelf registration statement earlier this year. The company maintains a strong financial position, with a proforma cash balance of around $84 million expected to support operations until 2027.
Additionally, Guggenheim Securities has increased its price target for Inflarx to $10 from $7, maintaining a Buy rating. This adjustment is based on the company’s clinical advancements and solid financial health. Inflarx recently reached a significant milestone by enrolling 30 patients in its Phase III trial of vilobelimab for ulcerative Pyoderma Gangrenosum, with interim results anticipated by May 2025. The European Commission has also granted marketing authorization for vilobelimab for SARS-CoV2-induced septic ARDS, marking a positive development for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.